Health
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
PRINCETON, N.J., August 29, 2025--Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology Congress 2025
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/fe20435ca3619c59fd4c0b8c72a22323"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/q36zex7IpryRl3VMOBC5Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fe20435ca3619c59fd4c0b8c72a22323","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Ze.yn_kGZT1ZPBRRV4vkmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/fe20435ca3619c59fd4c0b8c72a22323","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Findings from COLLIGO-HCM reinforce Camzyos’ efficacy and safety profile in reducing left ventricular outflow tract (LVOT) obstruction and improving symptom burden in a racially diverse, global patient population","length":212,"tagName":"p","attribs":{}},{"type":"text","content":"COLLIGO-HCM is a part of the WAYFARER-HCM global data program aimed at providing insights into use of Camzyos in real-world clinical practice","length":141,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., August 29, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today presented results from COLLIGO-HCM, a global retrospective real-world data study, in an oral session at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The analysis showed that Camzyos (mavacamten) was associated with reductions in left ventricular outflow tract (LVOT) obstruction and improvements in symptom burden in a racially diverse population of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) treated in an international, real-world setting. The effectiveness and safety demonstrated in COLLIGO-HCM are consistent with results from randomized, controlled clinical trials and further support the growing body of evidence for Camzyos, the first and only approved cardiac myosin inhibitor, as a standard of care for New York Heart Association (NYHA) class II-III symptomatic oHCM.","length":925,"tagName":"p"},{"type":"text","content":""Obstructive HCM can lead to considerable negative impact on patients’ lives," said Arnon Adler, MD, staff cardiologist at the Peter Munk Cardia...